(Q44255524)

1 December 2017

A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors (English)

1 reference

1 December 2017

1 reference

3

Charles S Fuchs

1 reference

1 December 2017

M Dror Michaelson

1

1 reference

1 December 2017

David P Ryan

2

1 reference

1 December 2017

Jeffrey G Supko

4

1 reference

1 December 2017

Rocio Garcia-Carbonero

5

1 reference

1 December 2017

J Paul Eder

6

1 reference

1 December 2017

Jeffrey W Clark

7

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

97

1 reference

1 December 2017

1

1 reference

1 December 2017

148-154

1 reference

Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents

1 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Mechanism of action of camptothecin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11038

7 January 2021

Identifiers

DOI

10.1002/CNCR.11038

1 reference

1 December 2017

1 reference